Noah Gilson, MD
Neurology · West Long Branch, NJNPI 1821054230
Payments from drug & device makers
Across 455 payments — averaging $1758.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$346K
- Eli Lilly$172K
- Novartis$137K
- Novo Nordisk AS$89K
- Merck$53K
- AbbVie$291
- plus $3K from 34 others
What the payments were for
- Food & beverage$3,55999%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 171 | $346,017 |
| Eli Lilly | 2 | $171,673 |
| Novartis | 59 | $137,376 |
| Novo Nordisk AS | 35 | $88,641 |
| Merck | 4 | $53,394 |
| AbbVie | 18 | $291 |
| UCB, Inc. | 17 | $266 |
| Jazz Pharmaceuticals Inc. | 15 | $222 |
| Amneal Pharmaceuticals LLC | 15 | $213 |
| Biogen | 11 | $202 |
| Pfizer | 11 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $129 |
| Amgen | 7 | $103 |
| Argenx US, Inc. | 7 | $102 |
| Genentech USA, Inc. | 7 | $100 |
| Genentech, Inc. | 1 | $100 |
| Tanabe Pharma America, Inc. | 6 | $87 |
| Lundbeck LLC | 5 | $80 |
| Biohaven Pharmaceuticals, Inc. | 5 | $76 |
| Supernus Pharmaceuticals, Inc. | 4 | $72 |
| Harmony Biosciences LLC | 5 | $67 |
| AstraZeneca | 4 | $59 |
| Adamas Pharmaceuticals, Inc. | 4 | $57 |
| Sanofi | 4 | $56 |
| Inspire Medical Systems, Inc. | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| SK Life Science, Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 2 | $29 |
| MDD US Operations, LLC | 2 | $29 |
| Johnson & Johnson | 2 | $27 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Amylyx Pharmaceuticals, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
| Promius Pharma LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Neurelis, Inc. | 1 | $12 |
How this compares
$799,954 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 35 | $514,575 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $321,604 |
| AustedoDeutetrabenazine | 11 | $187,001 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 20 | $178,975 |
| RytaryCarbidopa/Levodopa | 75 | $136,320 |
| KeppraLevetiracetam | 12 | $36,231 |
| Aimovig AutoinjectorErenumab-Aooe | 43 | $31,920 |
| LamictalLamotrigine | 34 | $28,859 |
| QuliptaAtogepant | 25 | $25,596 |
| UbrelvyUbrogepant | 21 | $24,814 |
| Nurtec OdtRimegepant Sulfate | 12 | $20,524 |
| Emgality PenGalcanezumab-Gnlm | 18 | $18,992 |
| TegretolCarbamazepine | 21 | $9,654 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 183 | $5,687 |
| Memantine Hcl | 120 | $5,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt | $195 | $535,09947 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $213 | $138,852127 claims |
| AbbVieQulipta, Ubrelvy | $291 | $50,41046 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in West Long Branch
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
- Machteld HillenNewark$999K
- Matthew TremblayLivingston$812K
- Matthew DavisMiddletown$785K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.